These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

953 related items for PubMed ID: 28807335

  • 1. Recent updates on grading and classification of neuroendocrine tumors.
    Kim JY, Hong SM, Ro JY.
    Ann Diagn Pathol; 2017 Aug; 29():11-16. PubMed ID: 28807335
    [Abstract] [Full Text] [Related]

  • 2. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
    Kim JY, Hong SM.
    Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
    [Abstract] [Full Text] [Related]

  • 3. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
    Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P.
    Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Digital image analysis of Ki67 hotspot detection and index counting in gastroenteropancreatic neuroendocrine neoplasms.
    Saetiew K, Angkathunyakul N, Hunnangkul S, Pongpaibul A.
    Ann Diagn Pathol; 2024 Aug; 71():152295. PubMed ID: 38547761
    [Abstract] [Full Text] [Related]

  • 8. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
    Kankava K, Maisonneuve P, Mangogna A, Centonze G, Cattaneo L, Prinzi N, Pusceddu S, Fazio N, Pisa E, Di Domenico S, Bertani E, Mazzaferro V, Albertelli M, Grillo F, Milione M.
    J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808
    [Abstract] [Full Text] [Related]

  • 9. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?
    Grillo F, Albertelli M, Annunziata F, Boschetti M, Caff A, Pigozzi S, Ferone D, Mastracci L.
    Endocrine; 2016 Jul; 53(1):58-62. PubMed ID: 26362059
    [Abstract] [Full Text] [Related]

  • 10. [Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy].
    Holzer K.
    Chirurg; 2014 Aug; 85(8):731-44. PubMed ID: 25103842
    [Abstract] [Full Text] [Related]

  • 11. [Clinicopathological characterization of gastro-entero- pancreatic neuroendocrine tumors].
    Borka K.
    Magy Onkol; 2018 Jul 20; 62(2):90-97. PubMed ID: 30027936
    [Abstract] [Full Text] [Related]

  • 12. [Clinicopathologic characteristics of 127 cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) studied in an oncology hospital].
    Alvarado-Cabrero I, de Anda-González J, Hernández-Hernández B, Mantilla-Morales A, Valencia-Cedillo R, Medrano-Guzmán R.
    Rev Gastroenterol Mex; 2012 Jul 20; 77(4):174-80. PubMed ID: 23142406
    [Abstract] [Full Text] [Related]

  • 13. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
    Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C.
    CA Cancer J Clin; 2024 Jul 20; 74(4):359-367. PubMed ID: 38685134
    [Abstract] [Full Text] [Related]

  • 14. Comparison of WHO 2000 and WHO 2010 classifications of gastroenteropancreatic neuroendocrine tumors.
    Karakuş E, Helvacı A, Ekinci O, Dursun A.
    Turk J Gastroenterol; 2014 Feb 20; 25(1):81-7. PubMed ID: 24918137
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Monitor-Image and Printout-Image Methods in Ki-67 Scoring of Gastroenteropancreatic Neuroendocrine Tumors.
    Dogukan FM, Yilmaz Ozguven B, Dogukan R, Kabukcuoglu F.
    Endocr Pathol; 2019 Mar 20; 30(1):17-23. PubMed ID: 30367334
    [Abstract] [Full Text] [Related]

  • 16. Pathology - grading and staging of GEP-NETs.
    Capelli P, Fassan M, Scarpa A.
    Best Pract Res Clin Gastroenterol; 2012 Dec 20; 26(6):705-17. PubMed ID: 23582914
    [Abstract] [Full Text] [Related]

  • 17. Hegemony and cost-effectiveness of endoscopic ultrasound (EUS) in the field of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs).
    De Angelis C, Manfrè SF, Bruno M, Pellicano R.
    Minerva Med; 2014 Oct 20; 105(5):363-70. PubMed ID: 25325565
    [Abstract] [Full Text] [Related]

  • 18. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M, Čačev T, Catela Ivković T, Marout J, Ulamec M, Zjačić-Rotkvić V, Kapitanović S.
    Mol Cell Endocrinol; 2016 Apr 15; 425():61-8. PubMed ID: 26805636
    [Abstract] [Full Text] [Related]

  • 19. Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature.
    Gaiani F, de'Angelis N, Minelli R, Kayali S, Carra MC, de'Angelis GL.
    Medicine (Baltimore); 2019 Sep 15; 98(37):e17154. PubMed ID: 31517859
    [Abstract] [Full Text] [Related]

  • 20. Principles of diagnosis and management of neuroendocrine tumours.
    Raphael MJ, Chan DL, Law C, Singh S.
    CMAJ; 2017 Mar 13; 189(10):E398-E404. PubMed ID: 28385820
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.